KLRB1 and neoplasm: By using CRISPR-Cas9 technology to edit the KLRB1 gene in human T cell co-culture experiments and humanized glioblastoma mouse models to inhibit this pathway, not only was T cell-mediated cytotoxicity enhanced, but tumor growth was also slowed and survival was prolonged (16).